Shulman DeMeo Asset Management LLC Has $1.70 Million Position in Johnson & Johnson (NYSE:JNJ)

Shulman DeMeo Asset Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,564 shares of the company’s stock after purchasing an additional 318 shares during the period. Johnson & Johnson makes up about 0.5% of Shulman DeMeo Asset Management LLC’s portfolio, making the stock its 19th biggest holding. Shulman DeMeo Asset Management LLC’s holdings in Johnson & Johnson were worth $1,695,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in JNJ. Family CFO Inc acquired a new position in Johnson & Johnson in the 4th quarter valued at $26,000. Steward Financial Group LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at $34,000. Joseph P. Lucia & Associates LLC bought a new position in shares of Johnson & Johnson in the 1st quarter valued at $38,000. Advocacy Wealth Management Services LLC increased its stake in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares during the last quarter. Finally, Gibson Wealth Advisors LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at $49,000. 68.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 0.6 %

Shares of JNJ opened at $170.71 on Thursday. The company has a market capitalization of $449.21 billion, a PE ratio of 23.01, a PEG ratio of 3.41 and a beta of 0.63. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The stock’s 50-day moving average price is $176.48 and its two-hundred day moving average price is $174.34. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. The firm had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.48 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.2 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.65%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s payout ratio is presently 60.92%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Credit Suisse Group lifted their price target on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research note on Wednesday, April 20th. Wells Fargo & Company lifted their price target on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Citigroup decreased their price target on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Finally, SVB Leerink reduced their price objective on Johnson & Johnson from $200.00 to $194.00 in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $191.13.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want More Great Investing Ideas?

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

This article was originally published by Etfdailynews.com. Read the original article here.